Laurus Labs Limited — Earnings Release 2025

Apr 24, 2025

April 24, 2025

==> picture [191 x 81] intentionally omitted <==

To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS

Dear Sir / Madam,

Sub: Press Release

Please find enclosed the Press Release on the Financial Results for the quarter and year ended March 31, 2025.

Please take the information on record.

Thanking you,

Yours sincerely,

For Laurus Labs Limited

VENKATESWAR Digitally signed by VENKATESWAR REDDY REDDY GOGIREDDY GOGIREDDY Date: 2025.04.24 15:17:52 +05'30'

G. Venkateswar Reddy

Company Secretary & Compliance Officer

Encl: A/a

==> picture [452 x 76] intentionally omitted <==

==> picture [218 x 93] intentionally omitted <==

Press Release

FOR IMMEDIATE RELEASE

24 APRIL, 2025

Laurus Labs Announces Full Year FY25 Results

Revenues at ₹ 5,554 Cr; EBITDA at ₹ 1,115 Cr, 20% margins

Hyderabad, April 24, 2025: Laurus Labs Ltd. ( Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028 ), a leading research and development driven pharmaceutical and biotech company in India announces its Q4 & Full Year FY25 results.

Financial Summary

[₹ Crore] except EPS amounts	4Q FY25	4Q FY24	Y-o-Y	FY25	FY24	Y-o-Y
Revenues	1,720	1,440	19%	5,554	5,041	10%
Gross Margins	54.5%	49.8%	4.7%	55.4%	51.7%	3.7%
EBITDA*	477	259	84%	1,115	798	40%
EBITDA Margins	27.7%	18.0%	9.7%	20.1%	15.8%	4.3%
PBT	312	107	192%	484	236	105%
Net Proft	234	76	208%	358	161	122%
EPS(Diluted)*	4.3	1.4	207%	6.6	2.9	128%

• Includes One-time gain of ₹ 59 Cr from sale of land in 4Q FY25, translating to ₹ 0.9 positive EPS impact (net of tax)

Dr. Satyanarayana Chava, Founder & Chief Executive Officer commented;

“We delivered a very good Q4 results and continued our transformative progress, reflecting robust demand for our CDMO offerings and meeting complex customer needs, supported by growth in FDF division. These results demonstrate the strength of our business model and give us confidence in our outlook. We are deepening our cooperation with major clients, and augmenting it with promising BD and capacity creation.

Our business remains well positioned to evolve into a well-diversified CMO/CDMO company with promising pipeline, enabling several technology platforms and commercial excellence, thanks to team commitment to the unified vision of delivering high quality integrated solution and securing our long-term growth potential.”

Corporate Office

2[nd] Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India T +91 40 6659 4333, 3980 4333, 2342 0500/501 F +91 40 6659 4320 / 3980 4320

Registered Office Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com

==> picture [169 x 72] intentionally omitted <==

V V Ravi Kumar, Executive Director & Chief Financial Officer commented;

“Despite the ongoing macroeconomic challenges, we have witnessed high level of demand for our offerings. For Q4, we delivered ₹ 1,720 Cr in revenues, growth of 19% and ₹ 477 Cr EBITDA grew by 84%, resulting in 27.7% margin. Gross margins remained healthy at 55% due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy.

Overall FY25 results, we have delivered revenues of ₹ 5,554 Cr, representing 10% growth and EBITDA stood at ₹ 1,115 Cr, growth of 40%. The EBITDA margin of 20.1% has substantially improved, supported by continuing operating leverage within CDMO business.

Going ahead, we remain confident in our growth expectations as we look forward to execute on long lead programs, new assets ramp up with revenue increasing over FY25 with continued focus on operational excellence. Our capital allocation strategy remain unchanged, prioritizing investments into high value business opportunities.”

Divisional Revenue Performance

[₹ Crore]	4Q FY25	4Q FY24	Y-o-Y	FY25	FY24	Y-o-Y
CDMO	490	265	85%	1,534	1,082	42%
Small molecules	461	236	95%	1,374	922	49%
Bio	29	29	0%	160	160	0%
Generics	1,230	1,175	5%	4,020	3,959	2%
API	686	745	-8%	2,438	2,545	-4%
FDF	544	430	27%	1,582	1,414	12%
Total Revenues	1,720	1,440	19%	5,554	5,041	10%
ARV Revenues*	803	708	13%	2,559	2,506	2%

• Includes API and Formulation (FDF) combined revenues

Summary Highlights:

• FY25 Revenues ₹ 5,554 Cr and 10% revenue growth and Q4 revenues accelerated driven by robust demand environment for our CDMO offering and higher FDF sales

• ₹ 1,115 Cr EBITDA with a margin of 20.1%, improvement is due to gradual step-up in the asset utilization. Gross margins maintained at healthy levels 55.4%, improving 3.7% pts over last year on positive product mix

• Q4 Revenues ₹ 1,720 Cr; +19% revenue growth, ₹ 477 Cr EBITDA; +84% growth resulted in a margin of 27.7%, Gross margins were at 54.5%

• Continued investments in growth projects with CAPEX at 12% of Revenue to support long term growth

• Declared second interim dividend of ₹ 0.8 per share during Q4 FY25

Divisional Highlights:

CDMO – Small molecules

• CDMO business reported revenues of ₹ 1,374 Cr, during FY25; increased by 49%

• Q4 Revenues of ₹ 461 Cr; increased by 95% Y/Y, driven by several mid-to-late stage NCE deliveries and steady increase in sales from new manufacturing assets

2

==> picture [169 x 72] intentionally omitted <==

• Multiple projects awarded in late phase & commercial phase programs, reflecting more trust from the industry on our comprehensive technology platforms, further solidifying growth potential

• Actively working on over 110 active projects in total (90 Human health and >20 in Animal and Crop Protection). On-going commercial supplies for over 15 products including few APIs as well as several intermediates

• Continue to invest in Vizag site, new DS block at Unit-4, Animal health DS facility MB4. During Q4, started the commercial operation at Crop protection facility

BIO

• Bio business reported revenues of ₹ 160 Cr, during FY25. The underlying performance is healthy excluding impact of advanced shipments last year and discontinued low margin non-core nutrition business, mainly led by strong demand in AOF portfolio

• Q4 Revenues of ₹ 29 Cr; flat Y/Y

• ₹ 120 Cr equity tranche from Eight Roads received, expect ground breaking for Largescale Fermentation facility in Vizag by next quarter - to commence operation by 2026 end

• Strong interest in enzyme engineering platform across small molecule clinical and commercial API projects

• Achieved 1.5x expansion in Client base in FY25 and over 180 clients supported

Generics

• Generics business reported revenues of ₹ 4,020 Cr, during FY25, increased by 2%

• Soft performance was due to capacity upgradation and low offtake in Oncology

• Q4 Revenues of ₹ 1,230 Cr; increased by 5% Y/Y and 27% Q/Q led by continued pick up in ARV and increase in developed market portfolio sales

• Multiple integrated CMO contract signed, supplies started. FDF manufacturing lines expansion on track – coming online by Dec-25

• Completed 1st phase investments in KRKA JV enabling land acquisition and meeting initial set-up cost for FDF facility. We expect to break ground by June-25 with focus to serve new markets including India

• Product filings update:

• DMF filings: 7 DMFs were filed in FY25. Cumulatively, 90 DMFs filed till date

• Developed market FDF filings: 7 product dossiers filed and a total of 6 approvals received (including Tentative approvals). Cumulatively, 87 product filed till date

Quality & ESG Highlights:

• We completed 160 Quality audit in FY25 including # 14 Regulatory & # 146 Customer audits, further demonstrating our robust QMS system and international standard cGMP production capacity

• Received Establishment Inspection Report (EIR) from USFDA for Unit-4 API manufacturing facility in Vizag (Inspection was conducted between 27[th] -31[st] Jan 2025)

• Acquired 26% equity in Kurnool Renewables (SPV) for ₹ 35Cr, enabling company to access 26 MW of renewable power (solar+wind) on captive mode basis. Additional renewable power source will be available from the quarter beginning Oct 2026.

• Multiple recognitions for EHS best practices received

• Laurus Labs inclusion in S&P Global Sustainability Yearbook 2025 and only Company to be named as “Industry Mover” this year from the Pharmaceuticals industry

3

==> picture [169 x 72] intentionally omitted <==

Earnings Conference Call

The company will organize a conference call on Thursday, April 24, 2025 at 5:00 p.m. IST to discuss Q4 & Full Year FY25 results followed by an interactive Q&A session from participants. All participants may join the call by dialing below numbers OR by using Diamond Pass link

Conference Dial-in
Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 101 2045
HongKong	+800 964 448
USA	+1 866 746 2133
UK	+0 808 101 1573
Express Join with Diamond Pass	Click here to register

Transcript of the conference call will be available on the Company’s website: www.lauruslabs.com

END

Media Relations

Karthik C T +91 40 3980 4380 | 9030088669 mediarelations@lauruslabs.com

Investors Relations

Vivek Kumar T +91 40 3980 4366 investorrelations@lauruslabs.com

About Laurus Labs

As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients.. Laurus Labs has three business divisions Generics (API+FDF), CDMO (Synthesis) and Bio. We have global leadership position in APIs, including anti-retroviral, oncology, cardiovascular, and gastro therapeutics. Our position was strengthened by our backwardintegration and strong regulatory compliance across all operations. We emerged as one of the most trusted CMO and Contract Development and Manufacturing Organization (CDMO) service provider to Global Innovators from drug development phase to commercial manufacturing. Laurus employs 7000+ people, including around 1,250+ scientists across 15 development & manufacturing sites approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2025 Laurus generated ₹ 5,554 crore in annual revenue and is listed on the BSE (Bombay Stock

4

==> picture [169 x 72] intentionally omitted <==

Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated “BBB” by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518.

For more information visit www.lauruslabs.com

Follow @ Laurus Labs on LinkedIn | Twitter | Facebook | Instagram

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

5